AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22032936 — intervention group
Group type: COMPARATOR
Intervention: Mixed picture‐word cues (control)
Number of subjects: 0
Study 19877110 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (basic training module)
Number of subjects: 2795
Study 19877110 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (specific modules)
Number of subjects: 2795
Study 19877110 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (overall)
Number of subjects: 2795
Study 17023828 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of moderate intensity exercise (intermittent run-walk on a treadmill at 70% to 85% of VO(2) peak)
Number of subjects: 10
Study 12833465 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m² on Days 1 and 8) and Cisplatin (70 mg/m² on Day 2) for 4 cycles (GC)
Number of subjects: 129
Study 12833465 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin (GC)
Number of subjects: 129
Study 12833465 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive adjuvant radiotherapy
Number of subjects: 129
Study 12833465 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy
Number of subjects: 129
Study 10642233 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted educational programme for 2.5 hours a week over six weeks, followed by a two-hour session of case discussion and debriefing.
Number of subjects: 108
Study 10642233 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 108
Study 10642233 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted educational programme.
Number of subjects: 108
Study 8878497 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine colonoscopy and carcinoembryonic antigen evaluation every three months, with colonoscopy performed preoperatively, 12 to 15 months after surgical treatment, and then at intervals of 12 to 24 months or when symptoms appeared.
Number of subjects: 481
Study 8878497 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic patients undergoing radical operation for recurrence.
Number of subjects: 481
Study 8878497 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen evaluation as a marker for recurrence.
Number of subjects: 481
Study 8878497 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy performed within the first 12 to 15 months after operation.
Number of subjects: 481
Study 1387849 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (12 IU/d)
Number of subjects: 42
Study 1387849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6395642 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 20
Study 6395642 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 20
Study 31197602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy patients with LOC eating
Number of subjects: 145
Study 30848697 — intervention group
Group type: EXPERIMENTAL
Intervention: del Nido Cardioplegia
Number of subjects: 56
Study 30848697 — intervention group
Group type: COMPARATOR
Intervention: blood Cardioplegia
Number of subjects: 56
Study 28437264 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 50 mg/kg intravenously for 10 min, followed by a continuous infusion of 15 mg/kg/h during surgery
Number of subjects: 66
Study 28437264 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 66
Study 28437264 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4
Number of subjects: 66
Study 26232277 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs
Number of subjects: 78
Study 26232277 — intervention group
Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 78
Study 26232277 — intervention group
Group type: COMPARATOR
Intervention: no-OAC
Number of subjects: 78
Study 24105269 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication tool in addition to the IPCRG sheet
Number of subjects: 114
Study 24105269 — intervention group
Group type: COMPARATOR
Intervention: IPCRG sheet only
Number of subjects: 114
Study 20833737 — intervention group
Group type: EXPERIMENTAL
Intervention: BILAG 2004 index
Number of subjects: 16
Study 20833737 — intervention group
Group type: EXPERIMENTAL
Intervention: SELENA flare instrument
Number of subjects: 16
Study 20833737 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's global assessment (PGA)
Number of subjects: 16
Study 20833737 — intervention group
Group type: EXPERIMENTAL
Intervention: BILAG 2004 flare
Number of subjects: 16
Study 20833737 — intervention group
Group type: EXPERIMENTAL
Intervention: SELENA flare
Number of subjects: 16
Study 20833737 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA
Number of subjects: 16
Study 18053002 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) administration at a dose of 0.4 g/kg daily for 6 months
Number of subjects: 39
Study 17086029 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators (ICDs)
Number of subjects: 0
Study 17086029 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary and primary prevention trials with ICDs
Number of subjects: 0
Study 12924170 — intervention group
Group type: EXPERIMENTAL
Intervention: One placebo tablet a day
Number of subjects: 197
Study 12924170 — intervention group
Group type: EXPERIMENTAL
Intervention: Two placebo tablets a day
Number of subjects: 197
Study 10941692 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategy for a primary prevention study testing aspirin
Number of subjects: 47453
Study 10941692 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups with 225 randomly selected 'eligible refusers'
Number of subjects: 47453
Study 9470874 — intervention group
Group type: EXPERIMENTAL
Intervention: Björk‐Shiley convexo‐concave (BScc) valve
Number of subjects: 137
Study 9470874 — intervention group
Group type: COMPARATOR
Intervention: Sorin Biomedical spherical valve
Number of subjects: 137
Study 8331700 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human superoxide dismutase (rhSOD, 3000 mg/day)
Number of subjects: 24
Study 8331700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3553277 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol powder (200 micrograms)
Number of subjects: 231
Study 3553277 — intervention group
Group type: COMPARATOR
Intervention: Albuterol aerosol (180 micrograms)
Number of subjects: 231
Study 29803772 — intervention group
Group type: EXPERIMENTAL
Intervention: CuSum-guided curriculum
Number of subjects: 46
Study 29803772 — intervention group
Group type: COMPARATOR
Intervention: Volume-based training arm
Number of subjects: 46
Study 26129873 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred music
Number of subjects: 14
Study 26129873 — intervention group
Group type: COMPARATOR
Intervention: Classical 'relaxation' music
Number of subjects: 14
Study 24477186 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (Thymoglobulin)
Number of subjects: 171
Study 24477186 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 171
Study 24477186 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 171
Study 24477186 — intervention group
Group type: COMPARATOR
Intervention: Combined groups A and C (Antithymocyte globulin and Daclizumab)
Number of subjects: 171
Study 24136691 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise heart rate monitors (HRMs) during guided mindfulness, diaphragmatic breathing, and progressive muscle relaxation techniques
Number of subjects: 53
Study 24136691 — intervention group
Group type: COMPARATOR
Intervention: Control group (techniques alone without HRM)
Number of subjects: 53
Study 21388442 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg once daily
Number of subjects: 379
Study 21388442 — intervention group
Group type: COMPARATOR
Intervention: exenatide 10 μg twice daily
Number of subjects: 379
Study 18513453 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (50 mg/kg/d BD)
Number of subjects: 103
Study 18513453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 17151174 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 63
Study 17151174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 12702894 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 450
Study 12702894 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 450
Study 12702894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 10896693 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (IGF-I) immunoreactivity in skin of ALS patients
Number of subjects: 34
Study 10896693 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 34
Study 10896693 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of illness in ALS patients
Number of subjects: 34
Study 8941104 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (n = 133; target dose, 25 to 50 mg BID)
Number of subjects: 278
Study 8941104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 145)
Number of subjects: 278
Study 1631473 — intervention group
Group type: EXPERIMENTAL
Intervention: Various medical and surgical treatments for endometriosis and medically assisted fertilization (IVF)
Number of subjects: 0
Study 2877327 — intervention group
Group type: COMPARATOR
Intervention: Highly rigid fixation
Number of subjects: 85
Study 2877327 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial micromovement applied across the fracture site for 30 min per day
Number of subjects: 85
Study 29954370 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing techniques educational session
Number of subjects: 2389
Study 29954370 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational session)
Number of subjects: 2389
Study 27604993 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment
Number of subjects: 1
Study 24100150 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rate brachytherapy (HDR-BT) with 2 × 8.5 Gy after external beam radiotherapy (EBRT) of 35.75 Gy in 13 fractions
Number of subjects: 108
Study 24100150 — intervention group
Group type: EXPERIMENTAL
Intervention: D₉₀ and V₁₀₀ at or above the second and third quartile
Number of subjects: 108
Study 24100150 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum D₉₀ of 108% of the prescribed dose
Number of subjects: 108
Study 21899956 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 65
Study 21899956 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stress induction)
Number of subjects: 65
Study 21899956 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressed group
Number of subjects: 65
Study 21899956 — intervention group
Group type: EXPERIMENTAL
Intervention: Females (in both groups)
Number of subjects: 65
Study 16052573 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), 20-25 mg/week
Number of subjects: 100
Study 16052573 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC), 2 mg/kg/day
Number of subjects: 100
Study 16052573 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 100
Study 16052573 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)
Number of subjects: 100
Study 12483765 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods based upon the variance ratio statistic
Number of subjects: 0
Study 12483765 — intervention group
Group type: EXPERIMENTAL
Intervention: Searle's method
Number of subjects: 0
Study 12483765 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted versions of Searle's method
Number of subjects: 0
Study 12483765 — intervention group
Group type: EXPERIMENTAL
Intervention: Thomas and Hultquist's method
Number of subjects: 0
Study 12483765 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 0
Study 12483765 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence intervals for the methods
Number of subjects: 0
Study 12483765 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from cluster based studies
Number of subjects: 0
Study 10921043 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with interventional therapy (chemotherapeutic drugs, biological response modifiers, or Chinese medicinal herbs)
Number of subjects: 60
Study 10921043 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 60
Study 7857502 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract LI 160 (3 x 300 mg daily)
Number of subjects: 135
Study 7857502 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (3 x 25 mg daily)
Number of subjects: 135
Study 7857502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (LI 160 and Imipramine)
Number of subjects: 135
Study 7857502 — intervention group
Group type: EXPERIMENTAL
Intervention: LI 160
Number of subjects: 135
Study 2519687 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bednets
Number of subjects: 16
Study 2519687 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated bednets
Number of subjects: 16
Study 792359 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin plus penicillin G (Amik-Pen)
Number of subjects: 50
Study 792359 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin plus carbenicillin (Amik-Carb)
Number of subjects: 50
Study 792359 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antibiotics with demonstrated synergy in vitro
Number of subjects: 50
Study 792359 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antibiotics without demonstrated synergy in vitro
Number of subjects: 50
Study 792359 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak serum antimicrobial dilution titer ≥ 1:8
Number of subjects: 50
Study 792359 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak serum antimicrobial dilution titer < 1:8
Number of subjects: 50
Study 30098003 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART (self-management for people with epilepsy)
Number of subjects: 60
Study 30098003 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART
Number of subjects: 60
Study 30098003 — intervention group
Group type: COMPARATOR
Intervention: WL (waitlist control)
Number of subjects: 60
Study 25806400 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mcg spinal morphine and 1 gram acetaminophen every 6 hours for 24 hours postoperatively
Number of subjects: 74
Study 25806400 — intervention group
Group type: COMPARATOR
Intervention: 150 mcg spinal morphine and placebo tablets
Number of subjects: 74
Study 25806400 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 25806400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 74
Study 24937546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (35,000 IU/wk)
Number of subjects: 160
Study 24937546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 22398159 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 100
Study 22398159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 20167176 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise program (group A, n = 8)
Number of subjects: 16
Study 20167176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense exercise program (group B)
Number of subjects: 16
Study 18382826 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the unaffected hemisphere (25 minutes)
Number of subjects: 20
Study 18382826 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 16088297 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsamodendron mukul (1.5 g/d)
Number of subjects: 57
Study 16088297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg/d)
Number of subjects: 57
Study 16088297 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with Balsamodendron mukul (1.5 g/d) and nifedipine (10 mg/d)
Number of subjects: 57
Study 16088297 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (untreated hypertensive patients)
Number of subjects: 57
Study 11861235 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formulas with reduced allergenicity
Number of subjects: 2252
Study 10438693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 75
Study 10438693 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 75
Study 7872385 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser photorefractive keratectomy using a multiple zone technique
Number of subjects: 12
Study 7872385 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatments performed on 4 patients
Number of subjects: 12
Study 7872385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen gas blowing during treatment
Number of subjects: 12
Study 7872385 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity loss
Number of subjects: 12
Study 2222103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering agents
Number of subjects: 0
Study 2222103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 151476 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion
Number of subjects: 23
Study 151476 — intervention group
Group type: COMPARATOR
Intervention: Control infusion with saline
Number of subjects: 23
Study 31571243 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate periodontal therapy (test group, n=46)
Number of subjects: 92
Study 31571243 — intervention group
Group type: COMPARATOR
Intervention: Delayed periodontal therapy (control group, n=46)
Number of subjects: 92
Study 31204146 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep pressure input during third molar extraction
Number of subjects: 0
Study 31204146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no deep pressure input)
Number of subjects: 0
Study 28930174 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (4 mg daily)
Number of subjects: 42
Study 28930174 — intervention group
Group type: COMPARATOR
Intervention: Control (0.05 mg daily)
Number of subjects: 42
Study 25369588 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric staining using CFSE and glycophorin A antibody
Number of subjects: 10
Study 25369588 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric staining using CFSE, glycophorin A antibody, and annexin V
Number of subjects: 10
Study 25369588 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between haemolysis rate (HR%) and number of microparticles detected
Number of subjects: 10
Study 23836515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular training (3 units per week for 12 weeks)
Number of subjects: 106
Study 23836515 — intervention group
Group type: COMPARATOR
Intervention: Attention control (regular discussion groups on coping strategies)
Number of subjects: 106
Study 21747355 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic atorvastatin (GA)
Number of subjects: 148
Study 21747355 — intervention group
Group type: COMPARATOR
Intervention: Reference atorvastatin (RA)
Number of subjects: 148
Study 20108741 — intervention group
Group type: EXPERIMENTAL
Intervention: commercial raisin bran cereal (cRB)
Number of subjects: 20
Study 20108741 — intervention group
Group type: EXPERIMENTAL
Intervention: bran flakes
Number of subjects: 20
Study 20108741 — intervention group
Group type: EXPERIMENTAL
Intervention: raisins
Number of subjects: 20
Study 20108741 — intervention group
Group type: EXPERIMENTAL
Intervention: experimental raisin bran cereal (eRB)
Number of subjects: 20
Study 20108741 — intervention group
Group type: COMPARATOR
Intervention: 10 percent sucrose
Number of subjects: 20
Study 20108741 — intervention group
Group type: COMPARATOR
Intervention: sorbitol
Number of subjects: 20
Study 17124819 — intervention group
Group type: EXPERIMENTAL
Intervention: PVL film dressing
Number of subjects: 49
Study 17124819 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 49
Study 15465940 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone consultation by nurses and paramedics using a computerized decision support system
Number of subjects: 635
Study 11704495 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 28
Study 11704495 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 28
Study 9129558 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg orally once a day for 4 days
Number of subjects: 9
Study 9129558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7939081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release formulation of valproate (Depakine Chrono)
Number of subjects: 13
Study 7939081 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation of valproate (Depakine)
Number of subjects: 13
Study 7939081 — intervention group
Group type: EXPERIMENTAL
Intervention: Valpromide (Depamide)
Number of subjects: 13
Study 3372076 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium aspartate hydrochloride (15 mmol per day for 6 months)
Number of subjects: 20
Study 3372076 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium supplementation)
Number of subjects: 20
Study 29058821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (120 mg)
Number of subjects: 60
Study 29058821 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg)
Number of subjects: 60
Study 29058821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27227485 — intervention group
Group type: EXPERIMENTAL
Intervention: T1ρ and T2 relaxation time measurements in the nucleus pulposus (NP) and annulus fibrosus (AF) of lumbar intervertebral discs
Number of subjects: 0
Study 27227485 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated T1ρ and T2 metrics
Number of subjects: 0
Study 25875447 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g dried ginger root powder (morning intake)
Number of subjects: 0
Study 25875447 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g dried ginger root powder (afternoon intake)
Number of subjects: 0